Stocks of major drug makers and biotech companies tumbled in the first full day of trading after Donald Trump announced that ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

President-elect Donald Trump has announced he wants to appoint vaccine sceptic Robert F Kennedy Jr as the head of the US ...

The Dow Jones Industrial Average (DJIA), one of the three main Wall Street benchmarks, succumbed to selling pressure in early ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Pharmaceutical stocks took a steep plunge in the wake of President Donald Trumps appointment of Robert F. Kennedy Jr. as ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...